A study published in Journal of Drugs in Dermatology described the outcomes of two phase 3 trials that demonstrated the efficacy and safety of halobetasol propionate (HP) 0.01% lotion in the treatment of moderate to severe plaque psoriasis. As psoriasis is a chronic, inflammatory disease that can differ in prevalence and clinical presentation among patients from various racial and ethnic groups, these post hoc studies evaluated HP 0.01% lotion in Hispanic participants.
During the study, participants were randomized (2:1) to receive once-daily HP or vehicle lotion for 8 weeks in addition to a 4-week posttreatment follow-up. These post hoc efficacy assessments in Hispanic participants (HP, n=76; vehicle, n=43) included treatment success (2‑grade improvement in Investigators Global Assessment [clear or almost clear]), psoriasis signs, and affected body surface area (BSA). Additionally, treatment-emergent adverse events (TEAEs) were evaluated.
The study noted that by week 8, 38.8% of participants achieved treatment success with HP vs 10.3% on vehicle (P=.001). Also, participants who received HP achieved greater improvements in psoriasis signs compared with vehicle (P=.01) and had a greater reduction in affected BSA vs vehicle (P=.001). The study also reported that treatment-related TEAEs with HP were application site infection and dermatitis (n=1 each).
Per the results, the study concluded that once-daily HP 0.01% lotion was linked to significant reductions in disease severity in Hispanic participants with moderate to severe psoriasis, with good tolerability and safety over the 8 weeks. –Jessica Garlewicz
Desai SR, Glick B, Del Rosso JQ, et al. Once-daily halobetasol propionate 0.01% lotion for moderate-to-severe plaque psoriasis: phase 3 analysis of Hispanic participants. J Drugs Dermatol. 2021;20(3):252-258. doi:10.36849/JDD.2021.5698